78 Johnson & Johnson to acquire $2 billion drug developer "Ambrx Biopharma" to treat Turbo Cancers with same tech as Pfizer's $43 billion Seagen acquisition. Both set their sights on 2025 Cancer TSUNAMI (twitter.com) 🤢 These people are sick! 🤮 posted 313 days ago by brain_dead 313 days ago by brain_dead +78 / -0 20 comments share 20 comments share save hide report block hide replies
Already done.